Company news
Neuroscientific Biopharmaceuticals Ltd. news in 2021
Neuroscientific Biopharmaceuticals Ltd.'s news releases, calls and decks from 2021, newest first.
Positive off-target safety assessment of EmtinB
December 23, 2021
Positive results in biomarker characterisation of Emtins
December 20, 2021
Completion of Safety Pharmacology Studies
October 17, 2021
NSB Receives R&D Advance & Overseas Finding
September 2, 2021
Positive Results in Multiple Sclerosis Study
August 30, 2021
2021 Annual Report and Appendix 4E
August 27, 2021
Results from Pulmonary Studies Clarification
August 20, 2021
Pause in Trading
August 19, 2021
Results from Pulmonary Studies
August 18, 2021
Quarterly Update and Appendix 4C
July 30, 2021
Successful completion of pivotal ocular safety study
July 1, 2021
NSB partners with Linear Research for Phase I Clinical Study
June 22, 2021
R&D Tax Rebate Received
May 31, 2021
Update on Pivotal Ocular Safety Studies
May 4, 2021
Appendix 4C - quarterly
April 29, 2021
Manufacturing Update
April 27, 2021
Key Executive Appointments to Support Clinical Studies
March 30, 2021
Decks in 2021
- ShareCafe Small Cap "Hidden Gems" Webinar (December 2021)
Conference · 13 slides · Dec 3, 2021
- Broker Briefing Investor Webinar (November 2021)
Conference · 13 slides · Nov 18, 2021
- BIO Europe 2021 and AusBiotech Invest 2021
Conference · 24 slides · Oct 26, 2021
- Share Café September 2021
Conference · 21 slides · Sep 3, 2021
- Gold Coast Investment Showcase 2021
Conference · 25 slides · Jun 23, 2021